Dr. Gennady Poda
Dr. Gennady Poda
Contact
Dr. Gennady Poda
Scientific Advisor and Group Leader, Computational Chemistry and Cheminformatics, Drug Discovery Program

gennady.poda@oicr.on.ca
gennadypoda@gmail.com

Scientific Advisor and Group Leader, Computational Chemistry and Cheminformatics, Drug Discovery Program

Dr. Gennady Poda is an expert in computational drug discovery.

He is Scientific Advisor and Group Leader, Computational Chemistry and Cheminformatics, in the Drug Discovery group at the Ontario Institute for Cancer Research (OICR) and Assistant Professor (Status) at the Leslie Dan Faculty of Pharmacy, University of Toronto.

Poda has a MSc in Molecular and Chemical Physics from the Moscow Institute of Physics and Technology and a PhD in Bioorganic Chemistry from the Institute for Bioorganic and Petrochemistry, National Academy of Sciences in Kiev, Ukraine. During his work at Pharmacia & Upjohn, Pfizer and now at OICR, he has demonstrated excellence in computer-aided drug design covering all aspects of modern computational drug discovery: structure-, ligand- and fragment-based drug discovery, cheminformatics, medicinal chemistry, data mining and analysis, physical and ADMET property prediction, methods development, and programming. He has made major contributions to late-stage pre-clinical discovery of drug leads in multiple therapeutic areas including disease-modifying antirheumatic drugs (DMARDs), antithrombotics, CNS analgesics, inhaled chronic obstructive pulmonary disease (COPD), COVID-19 and anti-cancer agents.

At OICR, Poda helped develop small molecule drug candidates for the treatment of haematological cancers that attracted major investments and partnership from Johnson & Johnson Innovation (C$450 million), Triphase Accelerator, and Celgene/Bristol Myers Squibb (US$1 billion). Most recently, Poda and his team received funding from the Ontario government’s COVID-19 Rapid Research Fund to identify new therapeutics and existing drugs that could be repurposed to treat COVID-19.

He is author and co-author of over 65 publications in peer-reviewed journals, 3 book chapters and 13 patents. He was recently a recipient of the OICR Extra Mile Award and three Innovative Spirit Awards in recognition of his structure-based and cheminformatics support of several on-going projects within OICR’s Drug Discovery Program.

Experience & Education
  • Principal Scientist/Sr. Principal Scientist, Computational Chemistry, Structural and Computational Chemistry group, Pfizer Global R & D, St. Louis, MO, U.S.
  • Scientist, Computational Chemistry, Structural and Computational Chemistry group, Pharmacia and Upjohn (acquired by Pfizer), St. Louis, MO, U.S.
  • Service Fellow, National Institute for Occupational Safety and Health (NIOSH) at the Centers for Disease Control and Prevention (CDC), Morgantown, VW, U.S.
  • Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN, U.S.
  • Laboratory of Theoretical Chemistry, University of Henri Poincare, Nancy-I, France
  • PhD, Bioogranic Chemistry, QSAR and Computational Chemistry, V.P. Kukhar Institute of Bioogranic Chemistry and Petrochemistry (IBOPC), National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • Master of Science, Molecular and Chemical Physics, Moscow Institute of Physics and Technology (MIPT), Moscow, U.S.S.R.
    Minor: Physiology of Nervous System, A.A. Bogomoletz Institute of Physiology, Kyiv, Ukraine
Current Affiliations
  • Scientific Advisor and Group Leader, Computational Chemistry and Cheminformatics, Drug Discovery, OICR
  • Assistant Professor (status only), Leslie Dan Faculty of Pharmacy, University of Toronto
  • Associate (Restricted) Graduate Faculty Member, Graduate Department of Pharmaceutical Sciences, University of Toronto
Select Publications
  • Posternak G, Tang X, Maisonneuve P, Jin T, Lavoie H, Daou S, Orlicky S, Goullet de Rugy  T, Caldwell L, Chan Kin, Aman A, Prakesch M, Poda G, Mader P, Wong C, Maier S, Kitaygorodsky J, Larsen B, Colwill K, Yin Zh, Ceccarelli DF, Batey RA, Taipale M, Kurinov I, Uehling D, Wrana J, Durocher D, Gingras A-C, Al-awar R, Therrien M, Sicheri F. “Functional characterization of a PROTAC directed against BRAF mutant V600E.” Nature Chem. Biol. 2020; 16: 1170-1178.
  • Saraon P, Snider J, Kalaidzidis T, Wybenga-Groot LE, Weiss K, Rai A, Radulovich N, Drecun L, Vuckovic N, Vucetic A, Wong V, Theriault B, Pham N-A, Park J, Datti A, Wang J, Pathmananthan S, Aboualizadeh F, Lyakisheva A, Yao Zh, Wang Y, Aman A, Moran MF, Poda G, Marcellus R, Uehling D, Samarzija M, Jakopovic M, Tsao M, Shepherd F, Sacher A, Leighl N, Akhmatova A, Al-awar R, Zerial M, Stagljar I. “A live-cell drug discovery platform for detection of compounds targeting receptor tyrosine kinases identifies inhibitors of osimertinib-resistant EGFR triple mutant.” Nature Chem Biol 2020; 16: 577-586.
  • Moustakim M, Christott T, Monteiro OP, Bennett J, Giroud C, Ward J, Rogers CM, Smith P, Panagakou I, Díaz-Sáez L, Felce S, Gamble V, Gileadi C, Halidi N, Heidenreich D, Chaikuad A, Knapp S, Huber KVM, Farnie G, Heer Jag, Manevski N, Poda G, Al-Awar R, Dixon DJ, Brennan PE, Fedorov O. “Discovery of an MLLT1/3 YEATS Domain Chemical Probe.” Angew Chem Int Ed Engl 2018; 57(50): 16302-16307.
  • Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Vittori S, Kuznetsova E, Smil D, Barsyte-Loverjoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senistera G, Schonegger A, Bilban M, Bock C, Brown PJ, Zuber J, Bennett K, Al-awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G. C/EBPa N-Terminal Leukemia is Sensitive to Pharmacological Targeting of the WDR5-MLL Interaction. Nature Chem Biol 2015; 11(8): 571-8.
  • Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the Therapeutic Potential of Human Kallikrein-Related Serine Peptidases. Nature Rev Drug Discov 2015; 14: 183-202.
Research Areas
Disease Areas
Opportunities to Collaborate

Dr. Poda is open to collaboration in these areas:

  • Drug Discovery
  • Computer-Aided Drug Design
  • Computational Chemistry
  • Cheminformatics
  • Machine Learning
  • In Silico ADMET
  • BIOVIA Pipeline Pilot
  • Prediction of binding affinities of protein-ligand interaction
  • Medicinal Chemistry
  • Protein-protein interaction
  • Cancer, immuno-oncology
  • COVID-19 drug repurposing
Patents
  • Al-awar, Rima; Isaac, Methvin; Chau, Anh M.; Mamai, Ahmed; Watson, Iain; Poda, Gennady; Subramanian, Pandiaraju; Wilson, Brian; Uehling, David “Tricyclic Inhibitors of the BCL6 BTB Domain Protein-Protein Interaction and Uses Thereof” (Ontario Institute for Cancer Research). US Patent App. 16/955,975, 2021.
  • Al-awar, Rima; Isaac, Methvin; Chau, Anh M.; Mamai, Ahmed; Watson, Iain; Poda, Gennady; Subramanian, Pandiaraju; Wilson, Brian; Uehling, David; Prakesch, Michael; Babu, Joseph; Morin, Justin-Alexander “Inhibitors of the BCL6 BTB Domain Protein-Protein Interaction and Uses Thereof” (Ontario Institute for Cancer Research). US Patent App. 16/690,924, 2020.
  • Al-awar, Rima; Isaac, Methvin; Joseph, Babu; Liu, Yong; Mamai, Ahmed; Poda, Gennady; Subramanian, Pandiaraju; Uehling, David; Wilson, Brian; Zepeda-Velazquez, Carlos “Inhibitors of WDR5 protein-protein binding” (Ontario Institute for Cancer Research), US Patent App. 16/643,633, 2020.
  • Al-awar, Rima; Zepeda-Velazquez, Carlos; Poda, Gennady; Isaac, Methvin; Uehling, David; Wilson, Brian; Joseph, Babu; Liu, Yong; Subramanian, Pandiaraju; Mamai, Ahmed; Prakesch, Michael; Stille, Julia K. “Inhibitors of WDR5 protein-protein binding” (Ontario Institute for Cancer Research), US Patent App. 16/080,866, 2019.
  • Al-awar, Rima; Zepeda-Velazquez, Carlos; Poda, Gennady; Isaac, Methvin; Uehling, David; Wilson, Brian; Joseph, Babu; Liu, Yong; Subramanian, Pandiaraju; Mamai, Ahmed “Inhibitors of WDR5 protein-protein binding” (Ontario Institute for Cancer Research), US Patent App. 16/080,851, 2019.
  • Sicheri, Frank; Postrnak, Ganna; Poda, Gennady. “Amide-based Proteolysis Modulators of B Rapidly Accelerated Fibrosarcoma (BRaf) and Associated Uses” (Ontario Institute for Cancer Research). US Patent Provisional Application No 62812567, March 1, 2019.
  • Al-awar, Rima; Isaac, Methvin; Chau, Anh M.; Mamai, Ahmed; Watson, Iain; Poda, Gennady; Subramanian, Pandiaraju; Wilson, Brian; Uehling, David “Tricyclic Inhibitors of the BCL6 BTB Domain Protein-Protein Interaction and Uses Thereof” (Ontario Institute for Cancer Research). WO/2019/119145, PCT/CA2018/051643, Priority to US 62/608,869, 2017.
  • Al-awar, Rima; Zepeda-Velazquez, Carlos; Poda, Gennady; Isaac, Methvin; Uehling, David; Wilson, Brian; Joseph, Babu; Liu, Yong; Subramanian, Pandiaraju; Mamai, Ahmed; Prakesch, Michael; Stille, Julia K. “Inhibitors of WDR5 protein-protein binding” (Ontario Institute for Cancer Research). WO/2017/147700, PCT/CA2017/050269, Priority to US 201662/301,673, 2017.
  • Al-awar, Rima; Zepeda, Carlos; Poda, Gennady; Isaac, Methvin; Uehling, David; Wilson, Brian; Joseph, Babu; Liu, Yong; Subramanian, Pandiaraju; Mamai, Ahmed; Prakesch, Michael; Stille, Julia K. “Inhibitors of WDR5 protein-protein binding” (Ontario Institute for Cancer Research). WO/2017/147701, PCT/CA2017/050271, Priority to US 201662/301,678, 2017.
  • Anderson, David R.; Mahoney, Matthew W.; Phillion, Dennis P.; Rogers, Thomas E.; Meyers, Marvin J.; Poda, Gennadiy; Hegde, Shridhar G.; Singh, Megh; Reitz, David B.; Wu, Kun K.; Buchler, Ingrid P.; Xie, Jin; Vernier, William F. “Preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds.” (Pharmacia Corporation, USA). PCT Int. Appl. (2004), WO 2004058762, A1 20040715, 573 pp.
  • Vernier, William, F.; Anderson, David R.; Phillion, Dennis P.; Meyers, Marvin J.; Hegde, Shridhar G.; Reitz, David B.; Buchler, Ingrid P.; Mahoney, Matthew W.; Rogers, Thomas E.; Poda, Gennadiy; Singh, Megh; Wu, Kun K.; Xie, Jin. “Mitogen Activated Protein Kinase-Activated Protein Kinase-2 Inhibiting Compounds” (Pharmacia Corporation, USA). US Patent Appl. (2004) US 2004/0209897 A1, 10/742,072, 567 pp.
  • Vazquez, Michael L.; Metz, Suzanne; Graneto, Matthew J.; Hanau, Cathleen E.; Mershon, Serena Marie; Hartmann, Susan J.; Reitz, David B.; Poda, Gennadiy; Lee, Len F.; Perry, Thao D.; Reinhard, Emily J.; Pugh, Leslie. “Cyclic Pyrazoles for the Inhibition of Mitogen Activated Protein Kinase-Activated Protein Kinase-2” (Pharmacia Corporation, USA). US Patent Appl. (2004) US 2004/0127492 A1, 10/369,055, 414 pp.
  • Anderson, David R.; Mahoney, Matthew W.; Phillion, Dennis P.; Rogers, Thomas E.; Meyers, Marvin J.; Poda, Gennadiy; Hegde, Shridhar G.; Singh, Megh; Reitz, David B.; Kun WU. K.; Buchler, Ingrid P.; Xie, Jin; Vernier, William F. “Mitogen Activated Protein Kinase-Activated Protein Kinase-2 Inhibiting Compounds” (Pharmacia Corporation, USA). Eur. Patent Appl. (2003) EP1572693, A1 EP20030814268.
Book Chapters
  • Poda, Gennady; Tanchuk, Vsevolod. “Computational Methods for the Discovery of Chemical Probes.” In: RSC Book Series “Discovery and Utility of Chemical Probes in Target Discovery”, Ed. Paul Brennan, RSC Press, Cambridge, 2020, 39-68.
  • Oliferenko, Polina V.; Oliferenko, Alexander A.; Poda, Gennady; Pillai, Girinath G.; Bernier, Ulrich R.; Agramonte, Natasha M.; Linthicum, Kenneth J. “Insect Olfactory System as the Target for Computer-Aided Design of Mosquito Repellents.” In: CRC Book Series “Computational Design of Chemicals for the Control of Mosquitoes and Mosquito-Borne Diseases”, Ed. James Devillers, January 2018, CRC Press.
  • Tetko, Igor V.; Poda, Gennadiy I. “Prediction of Log P with Property-Based Methods”. In: Methods and Principles in Medicinal Chemistry, 37 (Molecular Drug Properties), 381-406, 2008.
  • McFadyen, Iain; Metzger, Thomas; Subramanian, Govindan; Poda, Gennady; Jorvig, Erik; Ferguson, David M. “Molecular Modeling of Opioid Receptor-Ligand Complexes.” In: Progress in Medicinal Chemistry. Ed’s: Allen B. Reitz, and Scott L. Dax. 2002, v. 40, 107-135.
In the News
New potential treatment for leukemia discovered by OICR scientists draws major industry investment
New potential treatment for leukemia discovered by OICR scientists draws major industry investment
Jan 29, 2019
OICR Drug Discovery awarded for COVID-19 research
OICR Drug Discovery awarded for COVID-19 research
Jul 21, 2020